GSK stock holds steady as Indian CDSCO positive recommendation for RSV vaccine supports outlook

Traders Union
All News
Financial News
GSK drops 0.67% today to GBX1846.00

Highlights

GSK obtained a key regulatory recommendation in India for Arexvy, its RSV vaccine, based on positive Phase III data in the local population.
Arexvy is marketed in 68 countries for adults aged 60 and above, expanding GSK’s global vaccine footprint despite recent share price weakness.
GSK stock faces pronounced short-term selling pressure, with a likely trading range of GBX 1,820.00 to GBX 1,900.00 and further downside risk prevailing.

Indian regulatory progress as approval signals global expansion impetus

GSK plc received a favorable recommendation from India's Subject Expert Committee of the CDSCO for marketing approval of its Respiratory Syncytial Virus vaccine, Arexvy. This decision followed the assessment of Phase III trial results evaluating immunogenicity and safety data specific to the local population, which paves the way for GSK to expand regulatory access and commercial presence in the Indian healthcare market. Arexvy is already available in 68 countries for those aged 60 and above, highlighting the global rollout of this vaccine, though price action has remained under broader selling pressure.

Bearish momentum builds as technicals breach key support levels

GBX 1,846.00 is below the SMA-20 at GBX 2,044.00 and SMA-50 at GBX 2,060.26, but remains above the SMA-200 at GBX 1,796.69. The Ichimoku Kijun level sits at GBX 2,023.75, acting as immediate resistance. MACD signals a sell, and ADX indicates a weak bearish trend. Intraday oscillators reflect significant oversold conditions: RSI is at 28.26, CCI at -123.91, Stoch RSI at 6.87, and BBP at -77.64. The Awesome Oscillator is negative, supporting continued downward momentum. The session opened near yesterday's close and is trading close to today's low of GBX 1,842.50, with volatility remaining subdued and downside pressure prevailing.

Limited upside prospects as volatility constrains near-term direction

Over the next five trading days, expected price action for GSK is likely to remain within a typical volatility range of GBX 1,820.00 to GBX 1,900.00. The probability of a significant upward move remains below 20%, suggesting the dominant scenario is further downside or sideways stabilization near these levels. A break above the Ichimoku Kijun at GBX 2,023.75 would be needed to shift momentum toward recovery, while a move below GBX 1,820.00 could open the way for a test of the long-term SMA-200 as principal support.

Viktoras Karapetjanc, Traders Union expert, sees the CDSCO committee’s positive view on Arexvy as a constructive step for GSK’s global expansion. He believes regulatory momentum like this is a strong signal for the company’s fundamentals, even if price sentiment stays weak in the near term. The analyst notes oversold signals and weak volatility could lead to stabilization before any recovery attempt. In his view, an upside move may start if resistance at the Ichimoku Kijun is cleared. "India’s approval for Arexvy adds fuel to GSK’s long-term growth story — I am watching for a shift in momentum as the market digests this positive news."

Earlier, analysts noted that GSK was experiencing persistent technical weakness despite stable fundamentals, with downside risks dominating its near-term outlook. The current update reinforces this view, as continued oversold momentum and subdued volatility keep the focus on the risk of another leg down if GBX 1,820.00 is breached, making this level a critical marker for traders to monitor in the coming sessions.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.